Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell. / Hansen, Stine Bangsgaard; Højgaard, Lisbeth Drozd; Kastrup, Jens; Ekblond, Annette; Follin, Bjarke; Juhl, Morten.

In: Frontiers in Immunology, Vol. 13, 1085312, 2022.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hansen, SB, Højgaard, LD, Kastrup, J, Ekblond, A, Follin, B & Juhl, M 2022, 'Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell', Frontiers in Immunology, vol. 13, 1085312. https://doi.org/10.3389/fimmu.2022.1085312

APA

Hansen, S. B., Højgaard, L. D., Kastrup, J., Ekblond, A., Follin, B., & Juhl, M. (2022). Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell. Frontiers in Immunology, 13, [1085312]. https://doi.org/10.3389/fimmu.2022.1085312

Vancouver

Hansen SB, Højgaard LD, Kastrup J, Ekblond A, Follin B, Juhl M. Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell. Frontiers in Immunology. 2022;13. 1085312. https://doi.org/10.3389/fimmu.2022.1085312

Author

Hansen, Stine Bangsgaard ; Højgaard, Lisbeth Drozd ; Kastrup, Jens ; Ekblond, Annette ; Follin, Bjarke ; Juhl, Morten. / Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell. In: Frontiers in Immunology. 2022 ; Vol. 13.

Bibtex

@article{ea86646b71c24972b58dbbf63a66738e,
title = "Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell",
abstract = "The expeditious progress of Mesenchymal Stromal Cells (MSC) for therapeutic intervention calls for means to compare differences in potency of cell products. The differences may be attributed to innumerable sources including tissue origin, production methods, or even between batches. While the immunomodulatory potential of MSC is recognized and well-documented by an expansive body of evidence, the methodologies and findings vary markedly. In this study, we utilized flowcytometric analysis of lymphocyte proliferation based on cryopreserved peripheral blood mononuclear cells for quantification of the inhibitory effect of MSC. Technical aspects of fluorescent staining and cryopreservation of peripheral blood mononuclear cells were evaluated to obtain optimal results and increase feasibility. A range of common specific and unspecific mitogens was titrated to identify the conditions, in which the effects of Adipose tissue-derived Stromal Cells (ASC; a type of MSC) were most pronounced. Specific stimulation by antibody-mediated activation of CD3 and CD28 via TransAct and Dynabeads lead to substantial proliferation of lymphocytes, which was inhibited by ASC. These results were closely mirrored when applying unspecific stimulation in form of phytohemagglutinin (PHA), but not concanavalin A or pokeweed mitogen. The mixed lymphocyte reaction is a common assay which exploits alloreactivity between donors. While arguably more physiologic, the output of the assay often varies substantially, and the extent of proliferation is limited since the frequency of alloreactive cells is low, as opposed to the mitogens. To heighten the proliferative response and robustness, combinations of 2-5 donors were tested. Maximum proliferation was observed when combining 4 or more donors, which was efficiently suppressed by ASC. Several desirable and unfavorable traits can be attributed to the tested stimuli in the form of keywords. The importance of these traits should be scored on a laboratory-level to identify the ideal mitogen. In our case the ranking listed PHA as the most suited candidate. Developing robust assays is no trivial feat. By disclosing the full methodological framework in the present study, we hope to aid others in establishing functional metrics on the road to potency assays.",
keywords = "adipose tissue-derived stromal cell, flow cytometry, functional assay, lymphocyte proliferation assay, mesenchymal stromal cell, mitogen titration, potency assay development",
author = "Hansen, {Stine Bangsgaard} and H{\o}jgaard, {Lisbeth Drozd} and Jens Kastrup and Annette Ekblond and Bjarke Follin and Morten Juhl",
note = "Publisher Copyright: Copyright {\textcopyright} 2022 Hansen, H{\o}jgaard, Kastrup, Ekblond, Follin and Juhl.",
year = "2022",
doi = "10.3389/fimmu.2022.1085312",
language = "English",
volume = "13",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell

AU - Hansen, Stine Bangsgaard

AU - Højgaard, Lisbeth Drozd

AU - Kastrup, Jens

AU - Ekblond, Annette

AU - Follin, Bjarke

AU - Juhl, Morten

N1 - Publisher Copyright: Copyright © 2022 Hansen, Højgaard, Kastrup, Ekblond, Follin and Juhl.

PY - 2022

Y1 - 2022

N2 - The expeditious progress of Mesenchymal Stromal Cells (MSC) for therapeutic intervention calls for means to compare differences in potency of cell products. The differences may be attributed to innumerable sources including tissue origin, production methods, or even between batches. While the immunomodulatory potential of MSC is recognized and well-documented by an expansive body of evidence, the methodologies and findings vary markedly. In this study, we utilized flowcytometric analysis of lymphocyte proliferation based on cryopreserved peripheral blood mononuclear cells for quantification of the inhibitory effect of MSC. Technical aspects of fluorescent staining and cryopreservation of peripheral blood mononuclear cells were evaluated to obtain optimal results and increase feasibility. A range of common specific and unspecific mitogens was titrated to identify the conditions, in which the effects of Adipose tissue-derived Stromal Cells (ASC; a type of MSC) were most pronounced. Specific stimulation by antibody-mediated activation of CD3 and CD28 via TransAct and Dynabeads lead to substantial proliferation of lymphocytes, which was inhibited by ASC. These results were closely mirrored when applying unspecific stimulation in form of phytohemagglutinin (PHA), but not concanavalin A or pokeweed mitogen. The mixed lymphocyte reaction is a common assay which exploits alloreactivity between donors. While arguably more physiologic, the output of the assay often varies substantially, and the extent of proliferation is limited since the frequency of alloreactive cells is low, as opposed to the mitogens. To heighten the proliferative response and robustness, combinations of 2-5 donors were tested. Maximum proliferation was observed when combining 4 or more donors, which was efficiently suppressed by ASC. Several desirable and unfavorable traits can be attributed to the tested stimuli in the form of keywords. The importance of these traits should be scored on a laboratory-level to identify the ideal mitogen. In our case the ranking listed PHA as the most suited candidate. Developing robust assays is no trivial feat. By disclosing the full methodological framework in the present study, we hope to aid others in establishing functional metrics on the road to potency assays.

AB - The expeditious progress of Mesenchymal Stromal Cells (MSC) for therapeutic intervention calls for means to compare differences in potency of cell products. The differences may be attributed to innumerable sources including tissue origin, production methods, or even between batches. While the immunomodulatory potential of MSC is recognized and well-documented by an expansive body of evidence, the methodologies and findings vary markedly. In this study, we utilized flowcytometric analysis of lymphocyte proliferation based on cryopreserved peripheral blood mononuclear cells for quantification of the inhibitory effect of MSC. Technical aspects of fluorescent staining and cryopreservation of peripheral blood mononuclear cells were evaluated to obtain optimal results and increase feasibility. A range of common specific and unspecific mitogens was titrated to identify the conditions, in which the effects of Adipose tissue-derived Stromal Cells (ASC; a type of MSC) were most pronounced. Specific stimulation by antibody-mediated activation of CD3 and CD28 via TransAct and Dynabeads lead to substantial proliferation of lymphocytes, which was inhibited by ASC. These results were closely mirrored when applying unspecific stimulation in form of phytohemagglutinin (PHA), but not concanavalin A or pokeweed mitogen. The mixed lymphocyte reaction is a common assay which exploits alloreactivity between donors. While arguably more physiologic, the output of the assay often varies substantially, and the extent of proliferation is limited since the frequency of alloreactive cells is low, as opposed to the mitogens. To heighten the proliferative response and robustness, combinations of 2-5 donors were tested. Maximum proliferation was observed when combining 4 or more donors, which was efficiently suppressed by ASC. Several desirable and unfavorable traits can be attributed to the tested stimuli in the form of keywords. The importance of these traits should be scored on a laboratory-level to identify the ideal mitogen. In our case the ranking listed PHA as the most suited candidate. Developing robust assays is no trivial feat. By disclosing the full methodological framework in the present study, we hope to aid others in establishing functional metrics on the road to potency assays.

KW - adipose tissue-derived stromal cell

KW - flow cytometry

KW - functional assay

KW - lymphocyte proliferation assay

KW - mesenchymal stromal cell

KW - mitogen titration

KW - potency assay development

U2 - 10.3389/fimmu.2022.1085312

DO - 10.3389/fimmu.2022.1085312

M3 - Journal article

C2 - 36578497

AN - SCOPUS:85144960173

VL - 13

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 1085312

ER -

ID: 338355325